Suchen
Longeveron Inc
LGVNZur Watchlist hinzufügen
2.600USD
0.0000.00%
Trading geöffnet 09/23, 15:34（ET）
82.16MMarktkapitalisierung
VerlustKGV TTM
Über Longeveron Inc Unternehmen
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Longeveron Inc Profil
BörsenkürzelLGVN
Name des UnternehmensLongeveron Inc
IPO-datumFeb 12, 2021
CEOPowell (Than)
Anzahl der mitarbeiter25
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 12
Addresse1951 NW 7th Ave
StadtMIAMI
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33136
Telefon13053027158
Websitehttps://www.longeveron.com/
BörsenkürzelLGVN
IPO-datumFeb 12, 2021
CEOPowell (Than)
Führungskräfte von Longeveron Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
57.23K
+49.97%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
54.25K
+52.72%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
60.64K
+47.17%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
58.42K
-3.09%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Longeveron Inc?
Die fünf größten Anteilseigner von Longeveron Inc sind: Dr. Nataliya Agafonova, M.D.
Wie viele Institutionen halten Anteile an Longeveron Inc (LGVN)?
Mit Stand vom 2026Q1 halten 62 Institutionen Anteile an Longeveron Inc, mit einem Gesamtmarktwert von etwa 2.25M, was 8.08% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1131825.00 gestiegen.